menu

Treatments for Outpatients With Mild-to-Moderate COVID-19

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treatments for Outpatients With Mild-to-Moderate COVID-19

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
  • Overview

    Normal functions of the immune system include defense against infections. As the immune system ages and these capabilities decline, however, there is increased susceptibility to infections. Individuals of any age can acquire SARS-CoV-2 infection, although adults of middle age and older are most commonly affected, and older adults are more likely to have severe disease. Older age is also associated with increased COVID-19-related mortality. There is a need for knowledge regarding the harmful effects of the aging immune system (immunosenescence) and the role of chronic inflammation among elderly populations to facilitate enhanced clinical monitoring of at-risk patients. As such, an educational activity is needed to provide up-to-date coverage of the knowledge regarding immunosenescence in the context of COVID-19 to help optimize patient outcomes. 

  • Disclosure of Conflicts of Interest

    Disclosure Declaration
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose

    Faculty Disclosures

    Presenter
    Timothy E. Albertson, MD, MPH, PhD has disclosed the following relevant financial relationships: Consultant - J & J Covid vaccine case adjudication

    Planner
    Paul G. Auwaerter, MD, MBA, FIDSA has no financial relationships to disclose.

    Accredited Provider Disclosures
    Lance Azzo, PharmD, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Senior Director of Continuing Education & Compliance: has no financial relationships to disclose.
    Bernadette Makar, MSN, APRN-BC, NP-C, Nurse Planner/Reviewer: has no financial relationships to disclose. 

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    The intended audience for these activities includes Pulmonologists, Allergists, Primary Care Physicians, Nurse Practitioners, PAs, Nurses, and other healthcare providers who diagnose and manage patients with COVID-19.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • State the role of monoclonal antibodies in the treatment of coronavirus disease 2019 (COVID-19)
    • Compare and contrast current monoclonal antibody treatments available in the United States (US) via Emergency Use Authorization (EUA) with regard to administration, adverse events (AEs), and efficacy
    • Select appropriate candidates for monoclonal antibody treatment for mild-to-moderate COVID-19
    • Identify strategies to address health-care disparities
  • Accreditation and Credit Designation Statements

    CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare.

    In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until 9/06/2023. PAs should only claim credit commensurate with the extent of their participation.

    Nurses
    Credit being awarded: 1 ANCC contact hours.

    Nurse Practitioners

    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803
    This activity is approved for 1 contact hour(s) (which includes 1 hour(s) of pharmacology)

  • Disclaimer

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
  • Overview

    Normal functions of the immune system include defense against infections. As the immune system ages and these capabilities decline, however, there is increased susceptibility to infections. Individuals of any age can acquire SARS-CoV-2 infection, although adults of middle age and older are most commonly affected, and older adults are more likely to have severe disease. Older age is also associated with increased COVID-19-related mortality. There is a need for knowledge regarding the harmful effects of the aging immune system (immunosenescence) and the role of chronic inflammation among elderly populations to facilitate enhanced clinical monitoring of at-risk patients. As such, an educational activity is needed to provide up-to-date coverage of the knowledge regarding immunosenescence in the context of COVID-19 to help optimize patient outcomes. 

  • Disclosure of Conflicts of Interest

    Disclosure Declaration
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose

    Faculty Disclosures

    Presenter
    Timothy E. Albertson, MD, MPH, PhD has disclosed the following relevant financial relationships: Consultant - J & J Covid vaccine case adjudication

    Planner
    Paul G. Auwaerter, MD, MBA, FIDSA has no financial relationships to disclose.

    Accredited Provider Disclosures
    Lance Azzo, PharmD, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Senior Director of Continuing Education & Compliance: has no financial relationships to disclose.
    Bernadette Makar, MSN, APRN-BC, NP-C, Nurse Planner/Reviewer: has no financial relationships to disclose. 

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    The intended audience for these activities includes Pulmonologists, Allergists, Primary Care Physicians, Nurse Practitioners, PAs, Nurses, and other healthcare providers who diagnose and manage patients with COVID-19.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • State the role of monoclonal antibodies in the treatment of coronavirus disease 2019 (COVID-19)
    • Compare and contrast current monoclonal antibody treatments available in the United States (US) via Emergency Use Authorization (EUA) with regard to administration, adverse events (AEs), and efficacy
    • Select appropriate candidates for monoclonal antibody treatment for mild-to-moderate COVID-19
    • Identify strategies to address health-care disparities
  • Accreditation and Credit Designation Statements

    CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare.

    In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until 9/06/2023. PAs should only claim credit commensurate with the extent of their participation.

    Nurses
    Credit being awarded: 1 ANCC contact hours.

    Nurse Practitioners

    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803
    This activity is approved for 1 contact hour(s) (which includes 1 hour(s) of pharmacology)

  • Disclaimer

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule7 Dec 2022